Friday, February 28, 2020 | 12pm EST (NA) / 5pm GMT (UK) / 6pm CET (EU-Central) 60 min


There are many bioanalytical contract research organizations (CROs) that will provide quality bioanalytical services for a single project or perhaps even a single program for support of drug development. But how does a biopharma company trust to place additional projects or programs knowing they could be held hostage by the CRO to timelines and price if they place all of their eggs in one basket?


Another concern could be hearing that capacity has shifted to where they no longer have negotiated slots available or they have to set the priorities on competing resources. Contracting with another CRO could be feasible, but the current provider knows that will take too much time and energy and may even require the biopharma company to pay them not to do the work.


This webinar will demonstrate how KCAS utilizes forecasting and capacity tools to ensure clients get the results they want. Learn about different strategies to manage multiple projects seamlessly and mechanisms to help solve unpredictable issues and challenges that arise in every drug development program.




Dominic Warrino, Senior Scientific Advisor, Biopharmaceutical & Biomarker Services

Dominic Warrino serves as a scientific and technical advisor for both clients and internal teams for development, validation and application of bioanalytical, immunogenicity and biomarker methods for large molecule therapeutics. Dominic joined the company in 2013 and brought with him expertise in a full range of bioanalytical techniques including ECL, ELISA, RIA, flow cytometry, ELISpot, cell-based assays and Luminex. He has 20 years of experience developing and validating immunological assays for biotechnology and pharmaceutical companies. He most recently spent several years in the biopharma services department at Viracor-IBT (formally IBT), and previously also worked for Cytogen (formally Cellcor), Eligix and Streck Laboratories developing novel compounds for the treatment of various cancers. Dominic has worked on over 100 large molecule compounds developing and validating PK, PD, ADA, and biomarker assays in support of preclinical to Phase IV testing.


John Perkins, Senior Scientific Advisor, Pharmaceutical Services

John R. Perkins focuses on liquid chromatography/mass spectrometry (LC/MS) technologies in his role at KCAS. Previously, he was at Q2 Solutions and legacy companies for over 24 years working in quantitative LC/MS, principally with small molecules. His primary focus was on validation and sample analysis processes as well as managing customer relationships in Ithaca, NY. More recently he was responsible for the bioanalytical lab in Oss, The Netherlands.

John received his PhD in Supercritical Fluid Chromatography/Mass Spectrometry from the University of Wales, College of Cardiff, UK. He completed postdoctoral research on nanoscale separation techniques with mass spectrometry at NIEHS in Research Triangle Park. He earned his Bachelors degree in Chemistry from University of Reading, UK and a Masters degree in Advanced Analytical Chemistry from University of Bristol, UK.

Scroll to Top